Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single-center experience

Juvenile scleroderma (JS) is a group of diseases characterized byincreased skin thickness and fibrosis. It is the third-most commonrheumatic condition in childhood. There are two major forms of thedisease: juvenile localized scleroderma (JLS) and juvenile systemicsclerosis (JSSc), both classified into different subtypes depending onthe extent of the disease and the depth of the lesions.1 JLS, alsoknown as morphea, affects only the skin and subdermal tissues,while JSSc also includes fibrous changes in internal organs such asthe esophagus, intestines, heart, lungs, and kidneys